

# Bolin Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7252957/publications.pdf>

Version: 2024-02-01

67  
papers

4,936  
citations

94433

37  
h-index

123424

61  
g-index

69  
all docs

69  
docs citations

69  
times ranked

7230  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. <i>Cell Cycle</i> , 2009, 8, 909-915.	2.6	467
2	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. <i>Oncogene</i> , 2003, 22, 3205-3212.	5.9	406
3	Metformin induces unique biological and molecular responses in triple negative breast cancer cells. <i>Cell Cycle</i> , 2009, 8, 2031-2040.	2.6	376
4	Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase. <i>Molecular Cell</i> , 1998, 2, 581-591.	9.7	335
5	Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism. <i>Cancer Research</i> , 2011, 71, 4585-4597.	0.9	230
6	Anticancer Activity of the Antibiotic Clioquinol. <i>Cancer Research</i> , 2005, 65, 3389-3395.	0.9	209
7	Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin. <i>Cancer Research</i> , 2010, 70, 1204-1214.	0.9	207
8	Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. <i>Cell Cycle</i> , 2012, 11, 367-376.	2.6	178
9	Targeting of erbB3 receptor to overcome resistance in cancer treatment. <i>Molecular Cancer</i> , 2014, 13, 105.	19.2	142
10	Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. <i>International Journal of Cancer</i> , 2007, 120, 1874-1882.	5.1	134
11	Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. <i>Cell Cycle</i> , 2011, 10, 2959-2966.	2.6	128
12	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998, 16, 2087-2094.	5.9	122
13	Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. <i>Oncogene</i> , 2001, 20, 1913-1922.	5.9	107
14	Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 116, 652-657.	5.0	107
15	Glucose promotes breast cancer aggression and reduces metformin efficacy. <i>Cell Cycle</i> , 2013, 12, 3759-3769.	2.6	105
16	Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer. <i>Scientific Reports</i> , 2016, 6, 31093.	3.3	102
17	Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. <i>Cancer Research</i> , 2005, 65, 879-86.	0.9	82
18	Understanding the biology of HER3 receptor as a therapeutic target in human cancer. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 503-510.	12.0	80

#	ARTICLE	IF	CITATIONS
19	Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. <i>Breast Cancer Research</i> , 2005, 7, R589-97.	5.0	75
20	Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models. <i>Cancer Prevention Research</i> , 2014, 7, 199-210.	1.5	73
21	Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1864-1872.	4.1	61
22	HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression. <i>Cancer Research</i> , 2009, 69, 8403-8411.	0.9	60
23	Metformin attenuates transforming growth factor beta (TGF- $\beta^2$ ) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. <i>Cell Cycle</i> , 2016, 15, 1046-1059.	2.6	60
24	The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. <i>Molecular Cancer</i> , 2013, 12, 134.	19.2	56
25	Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. <i>Cancer Research</i> , 2003, 63, 2425-33.	0.9	54
26	Development of Effective Therapeutics Targeting HER3 for Cancer Treatment. <i>Biological Procedures Online</i> , 2019, 21, 5.	2.9	48
27	Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. <i>Nature Communications</i> , 2021, 12, 2699.	12.8	46
28	HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. <i>Cancer Letters</i> , 2011, 307, 72-79.	7.2	45
29	Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R101.	5.0	44
30	Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1389-1400.	4.1	44
31	Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. <i>Cancer Letters</i> , 2018, 420, 97-108.	7.2	44
32	HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. <i>Cancer Letters</i> , 2010, 296, 233-240.	7.2	43
33	Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer. <i>Molecular Carcinogenesis</i> , 2012, 51, 500-507.	2.7	43
34	MicroRNA regulation and therapeutic targeting of survivin in cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 20-31.	1.4	42
35	The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway. <i>Oncogene</i> , 2001, 20, 3726-3734.	5.9	40
36	Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. <i>Breast Cancer Research</i> , 2005, 7, R708-18.	5.0	40

#	ARTICLE	IF	CITATIONS
37	Cross-reactivity of C219 Anti-p170mdr-1 Antibody With p185c-erbB2 in Breast Cancer Cells: Cautions on Evaluating p170mdr-1. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1524-1529.	6.3	39
38	Role of erbB3 receptors in cancer therapeutic resistance. <i>Acta Biochimica Et Biophysica Sinica</i> , 2014, 46, 190-198.	2.0	37
39	A Novel Single Amino Acid Deletion Caspase-8 Mutant in Cancer Cells That Lost Proapoptotic Activity. <i>Journal of Biological Chemistry</i> , 2002, 277, 30159-30164.	3.4	35
40	Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. <i>Prostate</i> , 2001, 47, 21-28.	2.3	32
41	Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. <i>Carcinogenesis</i> , 2010, 31, 695-702.	2.8	32
42	MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 37693-37713.	1.8	28
43	Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. <i>Cancer Letters</i> , 2015, 366, 160-172.	7.2	27
44	Epigenetic mechanism of survivin dysregulation in human cancer. <i>Science China Life Sciences</i> , 2018, 61, 808-814.	4.9	26
45	Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling. <i>Molecular Cancer Research</i> , 2009, 7, 1882-1892.	3.4	23
46	Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. <i>Cancer Letters</i> , 2013, 335, 343-350.	7.2	23
47	Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. <i>BMC Cancer</i> , 2011, 11, 255.	2.6	21
48	The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. <i>Oncotarget</i> , 2016, 7, 2921-2935.	1.8	21
49	Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells. <i>Scientific Reports</i> , 2018, 8, 6829.	3.3	18
50	Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. <i>Cell Cycle</i> , 2018, 17, 985-996.	2.6	15
51	Effect of Photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. <i>Photodiagnosis and Photodynamic Therapy</i> , 2013, 10, 244-251.	2.6	13
52	Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells. <i>Biological Procedures Online</i> , 2018, 20, 16.	2.9	12
53	Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. <i>Oncotarget</i> , 2017, 8, 58847-58864.	1.8	12
54	miRNAs in cancers. <i>Cell Cycle</i> , 2013, 12, 3703-3704.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 585-597.	7.0	11
56	Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 303-314.	4.4	11
57	Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. , 2020, 3, 179-198.		11
58	Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 36-46.	0.0	10
59	Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 6143-56.	0.5	9
60	A New Caspase-8 Isoform Caspase-8s Increased Sensitivity to Apoptosis in Jurkat Cells. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-10.	3.0	8
61	Herceptin Conjugates Linked by EDC Boost Direct Tumor Cell Death via Programmed Tumor Cell Necrosis. <i>PLoS ONE</i> , 2011, 6, e23270.	2.5	8
62	ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2+ Breast Cancer Cells. <i>Anticancer Research</i> , 2017, 37, 6583-6591.	1.1	8
63	Preliminary study of cytotoxic effects of photodynamic therapy and immunotherapy on human pancreatic cancer cells. <i>Proceedings of SPIE</i> , 2009, , .	0.8	0
64	2-Chlorodeoxyadenosine (2-CDA) and Dexamethasone Induce Apoptosis in Multiple Myeloma (MM) Via Different Mechanisms.. <i>Blood</i> , 2007, 110, 4792-4792.	1.4	0
65	Abstract B042: Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab. , 2013, , .		0
66	Abstract A070: The erbB3 blocking antibody MM-121 resensitizes trastuzumab-resistant breast cancer cells to trastuzumab-mediated antitumor activity in vitro and in vivo. , 2013, , .		0
67	Sensitization of breast cancer to Herceptin by redox active nanoparticles. <i>American Journal of Cancer Research</i> , 2021, 11, 4884-4899.	1.4	0